ESMO 2022 | ORATOR: Surgical vs. non-surgical management of oropharyngeal cancer

Neil Gross, MD, FACS, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the ORATOR trials, which compared the safety and efficacy of surgical versus non-surgical treatments for patients with oropharyngeal cancer. ORATOR-1 (NCT01590355) did not show a clinically significant difference in swallowing outcomes, while ORATOR-2 (NCT03210103) closed early due to toxicity in surgical arm. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.